

4. Penta JS, Rosencweig M, Guarino AM. Mouse and large animal toxicology studies of 12 antitumor agents: relevance to starting doses for phase I clinical trials. *Cancer Chemotherapy Pharmacol* 1979; 3:97–101.
5. Chien JY, Mohutsky MA, Wrighton SA. Physiological approaches to the prediction of drug–drug interactions in study populations. *Curr Drug Metab* 2003; 4(5):347–356.
6. Nestorov I. Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. *Toxicol Lett* 2001; 120:411–420.
7. Pharmaceutical R&D Spending: Pharmaceutical Research and Manufacturers of America. PhRMA Annual Survey, 2001.
8. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *J Am Med Assoc* 1998; 279(15):1200–1205.
9. Martignoni M, Monshouwer M, de Kanter R, Pezzetta D, Moscone A, Grossi P. Phase I and Phase II metabolic activities are retained in liver slices from mouse, rat, dog, monkey and human after cryopreservation. *Toxicol In Vitro* 2003; 18(1):121–128.
10. Salonen JS, Nyman L, Boobis AR, Edwards RJ, Watts P, Lake BG, Price RJ, Renwick AB, Gomez-Lechon MJ, Castell JV, Ingelman-Sundberg M, Hidestrand M, Guillouzo A, Corcos L, Goldfarb PS, Lewis DF, Taavitsainen P, Pelkonen O. Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived *in vitro* systems. *Drug Metab Dispos* 2003; 31(9):1093–1102.
11. Bonate PL, Reith K, Weir S. Drug interaction at the renal level, implications for drug development. *Clin Pharmacokinet* 1998; 34(5):275–404.
12. Nestorov I. Whole body pharmacokinetic models. *Clin Pharmacokinet* 2003; 42(10):883–908.
13. Martin-Jimenez T, Riviere JE. Mixed-effects modeling of the interspecies pharmacokinetic scaling of oxytetracycline. *J Pharmaceut Sci* 2002; 91(2):331–341.
14. Mahmood I, Balian JD. The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. *Clin Pharmacokinet* 1999; 36(1):1–11.
15. Lin JH. Applications and limitations of interspecies scaling and *in vitro* extrapolation in pharmacokinetics. *Drug Metab Dispos* 1998; 26(12):1202–1212.
16. Davies B, Morris T. Physiological parameters in laboratory animals and humans. *Pharmaceut Res* 1993; 10(7):1093–1095.
17. Tugwood JD, Hollins LE, Cockerill MJ. Genomics and the search for novel biomarkers in toxicology. *Biomarkers* 2003; 8(2):79–92.
18. Marcusson-Stahl M, Cederbrant K. A flow-cytometric NK-cytotoxicity assay adapted for use in rat repeated dose toxicity studies. *Toxicology* 2003; 193(3):269–279.
19. Nagami K, Kawashima Y, Kuno H, Kemi M, Matsumoto H. *In vitro* cytotoxicity assay to screen compounds for apoptosis-inducing potential on lymphocytes and neutrophils. *J Toxicol Sci* 2002; 27(3):191–203.
20. Yang A, Cardona DL, Barile FA. *In vitro* cytotoxicity testing with fluorescence-based assays in cultured human lung and dermal cells. *Cell Biol Toxicol* 2002; 18(2):97–108.